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Abstract
Although genome-wide association studies (GWAS) have identified hundreds of complex trait loci, the pathomechanisms of
mostremainelusive.Studying thegeneticsofrisk factorspredisposingtodisease isanattractiveapproachtoidentify targetsfor
functional studies. Intracranial aneurysms (IA) are rupture-prone pouches at cerebral artery branching sites. IA is a complex
disease for which GWAS have identified five loci with strong association and a further 14 loci with suggestive association. To
decipher potential underlying disease mechanisms, we tested whether there are IA loci that convey their effect through
elevating blood pressure (BP), a strong risk factor of IA. We performed a meta-analysis of four population-based Finnish cohorts
(nFIN=11 266)notselected for IA, toassessthe association ofpreviouslyidentified IAcandidate loci(n=19)withBP. Wedefined
systolic BP(SBP), diastolic BP, meanarterial pressure, and pulse pressure as quantitative outcome variables. The most significant
result was further tested for association in the ICBP-GWAS cohort of 200 000 individuals. We found that the suggestive IA locus
at5q23.2inPRDM6wassignificantlyassociatedwithSBPinindividualsofEuropeandescent(pFIN=3.01E-05, pICBP-GWAS=0.0007,
pALL=8.13E-07). The risk allele of IA was associated with higher SBP. PRDM6 encodes a protein predominantly expressed in
vascular smooth muscle cells. Our study connects a complex disease (IA) locus with a common risk factor for the disease (SBP).
We hypothesize that common variants in PRDM6 can contribute to altered vascular wall structure, hence increasing SBP and
predisposing to IA. True positive associations often fail to reach genome-wide significance in GWAS. Our findings show that
analysis of traditional risk factors as intermediate phenotypes is an effective tool for deciphering hidden heritability. Further, we
demonstrate that common disease loci identified in a population isolate may bear wider significance.
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Introduction
Intracranial aneurysms (IA) are berry-shaped pouches at the
branching sites of cerebral arteries. 2–5% of the world population
is estimated to harbor IA [1]. Most IA go unnoticed during one’s
lifetime. However, when they become symptomatic, it is usually
due to rupture, causing subarachnoid hemorrhage (SAH). SAH is
devastating intracranial bleeding, and half of those with SAH die
within a year [2,3]. SAH affects the working age population, with
a median age of 55 [4]. Its incidence in Finland is 19/100 000/
year [5,6], triple than that of the rest of the world. The reason for
this higher than average incidence is unknown. Aneurysmal SAH
places a heavy burden on society both emotionally and financially.
The strongest known non-modifiable risk factor of SAH is family
history of the disease, and the strongest modifiable risk factors are
smoking, excessive alcohol intake, and hypertension [7]. An
important step in tackling SAH is to understand why IAs develop.
Our understanding of the environmental and genetic back-
ground of IA formation is limited. Positive family history of IA or
SAH, older age and female sex increase the risk of developing IA
[1]. Of the general cardiovascular risk factors, smoking has been
shown to increase the risk of IA formation [8], and high blood
pressure has long been speculated to do so [9]. The high, often
undocumented, prevalence of high blood pressure in the control
populations is likely the reason why it frequently fails to reach
statistical significance as an IA risk factor [1]. Chronic hyperten-
sion may contribute to IA formation by imposing constantly high
shear stress on vascular walls [9].
Multiple factors, such as familial aggregation of the disease,
make a genetic contribution likely to the risk of IA. A minority of
IAs show familial aggregation (under 10%) [7]. Linkage studies in
IA families have highlighted numerous genetic regions and a
recent exome sequencing study identified coding mutations in
familial thoracic aortic aneurysm with intracranial aneurysm [10].
However, the majority of IA is sporadic. Sporadic IA is a complex
disease and no gene with a certain role has been identified yet.
Recent genome-wide association studies (GWAS) [11,12] involv-
ing Finnish IA patients, have attempted to decipher the complex
genetic background of IA. From these studies, five loci emerged
with strong association to IA (p,5E-07, posterior probability of
association –PPA.0.5), with the highest statistical significance at
9p21.3, a risk locus of multiple cardiovascular diseases. Further 14
loci exhibited suggestive association to IA (0.1#PPA,0.5).
Despite the success of GWAS in identifying IA susceptibility
loci, the pathomechanism by which they contribute to IA
formation remains elusive. We hypothesize that hypertension, a
strong modifiable risk factor of IA, may possess an overlapping
genetic background with IA. To test this hypothesis, we analyzed
the IA loci so far identified, in well-characterized population-based
cohorts consisting of more than 210 000 individuals with blood
pressure measurements.
Results
41 SNPs from 19 independent IA loci [13] were first analyzed
for association with blood pressure in the national Health 2000
survey (H2000) [14] discovery cohort of 1581 individuals without
blood pressure lowering medication (Table S1). We adjusted the
analysis for age and gender (ROBUST model). The most
significant association (p,0.1) were observed at 2q33.1 with
diastolic blood pressure (DBP) and with mean arterial pressure
(MAP), at 4q31.23 and 19q13.12 with DBP, and at 5q23.2 with
systolic blood pressure (SBP), DBP, and MAP. We did not detect
association with pulse pressure (PP) (Table S1). Next, we wanted to
analyze the independence of the association signals observed. We
tested all 19 loci SNPs adjusting for further factors known to affect
blood pressure, namely smoking habits, alcohol consumption, and
body mass index (BMI) (ADVANCED model). There was no
tendency of association with DBP at 4q31.23 and 19q13.12 with
the ADVANCED model. The strength of the association
decreased for the four SNPs at the 2q33.1 locus for SBP, but
increased marginally for DBP, and MAP. At 5q23.2 the strength
of association increased substantially for most blood pressure
measurements, such as SBP, DBP, and MAP (Table 1 and Table
S2) for all three SNPs tested. The IA risk alleles at 5q23.2 were
associated with elevated blood pressure.
To confirm the initial association signals at the 2q33.1 and
5q23.2 loci observed in the H2000 discovery cohort, we tested
them for association with blood pressure in three additional
population-based cohorts from Finland. SNPs at 2q33.1 failed to
show significant association with DBP and MAP in any of the
replication cohorts (the Cardiovascular Risk in Young Finns
Study-YFS [15,16], the Northern Finland Birth Cohort 1966-
NFBC1966 [17], and the Helsinki Birth Cohort Study-HBCS
[18]). When the results were combined from all cohorts in a fixed
effect meta-analysis, they remained non-significant (Table 2). At
5q23.2 SNPs showed significant association with SBP in YFS and
NFBC1966 (Table 1). In HBCS, although consistent in the
direction of the effect, the association remained suggestive. When
the results were combined from all cohorts in a fixed effect meta-
analysis, we detected significant association with SBP at 5q23.2
(prs570682=4.80E-05, prs2287696=6.81E-05, prs335206=3.01E-05)
(Table 1). Comparing the mean SBP of the study participants
stratified for their 5q.23.2 genotypes indicated a positive
correlation between the number of risk alleles and higher SBP
for all three SNPs tested (Figure 1). Study participants homozygous
for the risk allele (C, in the case of rs335206), had on average 1.3
Hgmm higher SBP compared to those who were homozygous for
the protective allele, and 0.9 Hgmm higher than those with the
heterozygous genotype. This effect size is comparable to those of
most blood pressure loci identified by The International
Consortium for Blood Pressure Genome-wide Association Studies
(ICBP-GWAS) consortium [19]. The observed linear effect of risk
allele count is strongly suggestive of a true association. Association
at 5q23.2 with DBP (prs570682=0.02, prs2287696=0.04,
prs335206=0.03) and MAP (prs570682=0.0007, prs2287696=0.0010,
prs335206=0.0004) showed a reduction of significance when results
were combined from all cohorts (Table S2).
To test whether the association at the 5q23.2 locus is unique to
the Finnish cohorts, we attempted to replicate the association with
the three SNPs in the multinational cohort ICBP-GWAS [19]. All
three SNPs showed significant association with SBP
(prs570682=0.0065, prs2287696=0.00079, prs335206=0.0014) in the
ICBP-GWAS cohort of 200 000 individuals of European descent.
The risk allele for elevated SBP in the ICBP-GWAS cohort was
the same as in our meta-analysis of four Finnish population-based
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combined with the ICBP-GWAS results in a fixed effect meta-
analysis, the strength of the association increased with all three
SNPs tested (Table 3). The strongest association was observed with
rs2287696 (pALL=8.13E-07). This suggests that the variant at
5q23.2 is a common risk factor present in multiple populations of
European descent. Further loci or results for DBP or MAP were
not tested for association in ICBP-GWAS, since they failed to
show significant association in our replication cohorts.
All three tested SNPs at 5q23.2 reside in intronic regions of the
gene PR domain containing 6 (short form: PRDM6) and showed
comparable p-values. To further explore the associated region in
an attempt to pinpoint the causative variant, we examined all 1000
Genomes variants around PRDM6 in the four Finnish cohorts
(Figure 2). The strongest association was observed with rs163189
(p=6.12E-06) near rs570682 and rs2287696, in the second intron,
where the most significantly associated SNPs clustered. All five of
the strongest associated SNPs are located within a 4.7 kb region at
122.4 MB (Human genome build 36), surrounding a Sterol
regulatory element binding transcription factor 1 (SREBP1)
binding site (Figure 2) [20].
Discussion
Hypertension, a leading cardiovascular risk factor, is a strong
modifiable risk factor for IA and its deadly rupture. Our study
establishes a genetic link between elevated SBP and IA formation.
Further, we demonstrate the benefits of using population isolates
for mapping complex disease loci valid in multiple populations.
5q23.2 was identified as a suggestive IA risk locus by Yasuno
and colleagues [13] in a multinational GWAS including Finnish
IA patients. The strength of the association at 5q23.2 in their
study mainly came from the Finnish cohort (Figure S1). However,
albeit weaker, association to IA at 5q23.2 was observable in all
cohorts tested by Yasuno and colleagues. In the two tier approach
we applied, the suggestive aneurysmal locus at 5q23.2 showed
robust association to blood pressure traits in three cohorts
(namely the discovery cohort H2000, and the replication cohorts
NFBC1966 and YFS). The trend of the effect was the same while
the association remained suggestive with blood pressure traits in
the HBCS. HBCS participants’ average age was higher (61 years)
than that of the rest (36 years) (Figure S2). With age, the relative
contribution of genetic predisposition and lifestyle may change,
potentially accounting for the less significant association in
HBCS.
In our meta-analysis of candidate loci the most significant
association was observed at 5q23.2 in PRDM6. Although an
association can be observed throughout the whole gene, fine-
mapping of the region with 1000 Genomes variants revealed the
focus of association to be within a 4.7 kb region in the second
intron (Figure 2). PRDM6 encodes an epigenetic modulator of
transcription with roles in endothelial [21] and vascular smooth
muscle cells (SMC) [22]. PRDM6 has a critical role in arterial wall
Author Summary
When multiple genes or genetic regions contribute to the
inherited risk of a disease, it is referred to as a complex
disease. Genome-wide association studies (GWAS) aim to
detect common genetic variations that associate with
complex traits or diseases. Although GWAS have been
successful in identifying strongly associated genetic loci,
they lack the means to point out true, but less strong,
associations. Studying conditions that are related to the
disease of interest can help sort out less strong
associations. Intracranial aneurysms (IA) are berry-like
dilations in cerebral arteries. Most IAs do not give
symptoms until they bleed, causing a highly fatal form of
stroke. Half of the people who suffer bleeding of an IA die.
IA is a complex disease. Both inherited risk and environ-
mental factors contribute to the risk of developing IA.
Women, smokers, those with high alcohol intake or high
blood pressure are more prone to develop IA and
bleeding. GWAS found 19 genetic regions increasing the
risk of IA. Here we show that one of these loci, on the long
arm of chromosome 5, in addition to raising IA risk also
increases systolic blood pressure. We speculate that the
cause is modified vascular wall structure.
Table 1. 2q33.1 and 5q23.2 loci cohort-wise ADVANCED model effect estimates and meta-analysis results with systolic blood
pressure (SBP).
$
Discovery -
beta (SE) Replication - beta (SE) Meta SBP*
Locus SNP IA Risk Allele MAF H2000 YFS NFBC1966 HBCS p beta (SE)
2q33.1 rs1429412 G 0.5 0.75 (0.64) 20.27 (0.42) 20.15 (0.24) 0.05 (0.85) 6.65E-01 20.08 (0.19)
2q33.1 rs12472355 A 0.5 0.73 (0.64) 20.24 (0.42) 20.11 (0.24) 20.03 (0.85) 7.71E-01 20.06 (0.19)
2q33.1 rs787997 A 0.4 0.62 (0.65) 20.11 (0.42) 20.08 (0.24) 0.25 (0.84) 9.66E-01 20.01 (0.19)
2q33.1 rs787994 T 0.4 0.68 (0.65) 0.03 (0.42) 20.03 (0.24) 0.26 (0.85) 7.53E-01 0.06 (0.19)
5q23.2 rs570682 T 0.2 1.48 (0.69) 1.22 (0.47) 0.71 (0.27) 0.46 (0.98) 4.80E-05 0.87 (0.22)
5q23.2 rs2287696 A 0.2 1.68 (0.71) 1.18 (0.49) 0.67 (0.28) 0.93 (1.03) 6.81E-05 0.89 (0.22)
5q23.2 rs335206 C 0.4 1.02 (0.60) 0.85 (0.40) 0.74 (0.24) 0.60 (0.84) 3.01E-05 0.79 (0.19)
Genomic positions are based on the human genome build 36. Alleles are reported on the forward strand of the reference genome. The effects are reported for the
alleles increasing risk for IA in the Yasuno et al. studies [12,13]. Risk alleles are aligned according to the forward strand of the reference genome. Minor allele frequencies
(MAF) are based on from the HapMap Phase II CEU population data.
$Diastolic blood pressure (DBP) and mean arterial pressure (MAP) association results from 2q33.1 and 5q23.2 SNP are in Table S2.
*Meta SBP: meta-analysis of discovery and replication cohort p-values and beta for systolic blood pressure (SBP) with the ADVANCED model. Association analyses were
corrected for gender, age, BMI, smoking habits and alcohol consumption.
SE: standard error.
doi:10.1371/journal.pgen.1002563.t001
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in the phenotypic switch between proliferative and differentiating
vascular SMC phenotypes [22]; when active, PRDM6 inhibits
differentiation and promotes proliferation. Excess vascular SMC
proliferation is an important pathomechanism in hypertension,
and it exacerbates the vascular wall remodeling often seen in IA
[23,24]. When vascular SMCs re-enter the cell cycle to proliferate,
they lose their contractile qualities. Distinct from extracranial
arteries, cerebral arteries lack an external elastic lamina and the
adventitia is weakly developed, making them inflexible, and less
resistant to stress [25]. It is possible that when SMC proliferation
further stiffens cerebral arteries, they become incapable of
adjusting to shear stress, and give way to IA formation. This is a
plausible explanation to why the intracranial manifestation of a
supposedly generalized vasculopathy can be so distinct. Intrigu-
ingly, excessive vascular SMC proliferation is part of the
pathomechanism of the strongest common IA risk locus at
9p21.3 [26]. However, to test possible causality, examination of
whether the risk variant at 5q23.2 is associated with higher
PRDM6 activity is necessary. Although the causative variant
Table 2. Summary of leading SNPs from the 19 loci showing strong or suggestive association with IA in a multinational GWAS
containing Finnish patients [12].
Representative SNPs of IA loci with PPA.0.5 (Yasuno et al 2010 [12])
IA GWAS (Yasuno et al. 2010)
#
SBP meta-analysis with
ROBUST model
$
SBP meta-analysis
with ADVANCED
model
$
Locus SNP Position Gene Risk Allele Finnish p OR (95% CI) PPA
## beta (SE) p beta (SE) p
8q12.1 rs9298506* 55600077 39-SOX17 A 1.00E-05 1.39(1.20–1.61) 0.9999 20.03 (0.23) 8.80E-01 20.09 (0.22) 6.79E-01
9p21.3 rs1333040 22073404 CDKN2A/B T 5.30E-08 1.39(1.23–1.56) 0.9999 0.07 (0.19) 7.20E-01 20.04 (0.19) 8.24E-01
10q24.32 rs12413409 104709086 CNNM2 G 4.20E-02 1.27(1.01–1.59) 0.9990 0.62 (0.35) 7.78E-02 0.67 (0.34) 4.99E-02
13q13.1 rs9315204 32591837 STARD13 T 1.70E-04 1.27(1.12–1.44) 0.9981 0.04 (0.21) 8.64E-01 0.12 (0.20) 5.51E-01
18q11.2 rs11661542 18477693 RBBP8 C 2.30E-02 1.14(1.02–1.28) 0.9999 0.00 (0.20) 9.81E-01 0.00 (0.19) 9.86E-01
Representative SNPs of IA loci with 0.1#PPA,0.5 (Yasuno et al 2011 [13])
IA GWAS (Yasuno et al. 2010)
#
SBP meta-analysis
with ROBUST model
$
SBP meta-analysis with
ADVANCED model
$
Locus SNP Position Gene Risk Allele Finnish p OR (95% CI) PPA
## beta (SE) p beta (SE) p
1p36.31 rs1876848 6876262 CAMTA1 G 1.30E-01 1.12 (0.97–1.30) 0.1128 0.03 (0.24) 8.98E-01 20.09 (0.23) 6.87E-01
1p22.2 rs1725390 91031160 BARHL2-ZNF644 A 1.40E-03 1.21 (1.08–1.36) 0.1011 20.08 (0.20) 6.72E-01 20.13 (0.19) 4.92E-01
1q21.3 rs905938 153258013 DCST2 T 6.70E-03 1.22 (1.06–1.41) 0.1252 0.38 (0.23) 9.96E-02 0.37 (0.22) 9.91E-02
2q33.1 rs787994 197931366 ANKRD44-SF3B1 T 2.90E-04 1.25 (1.11–1.41) 0.0988 0.25 (0.20) 2.11E-01 20.06 (0.19) 7.53E-01
4q31.23 rs6841581* 148620640 upstream EDNRA G 4.00E-03 1.31 (1.09–1.58) 0.1750 0.11 (0.28) 6.91E-01 0.16 (0.27) 5.54E-01
5q23.2 rs2287696 122488231 PRDM6 A 3.60E-04 1.28 (1.12–1.46) 0.1760 0.87 (0.23) 1.83E-04 0.89 (0.22) 6.81E-05
8p23.2 rs2045637 2963188 CSMD1 A 9.20E-05 1.37 (1.17–1.61) 0.2139 0.31 (0.28) 2.61E-01 0.35 (0.27) 1.95E-01
8q24.23 rs6577930** 139582362 FAM135B-
COL22A1
T 3.00E-03 1.21 (1.11–1.33) 0.1386 20.01 (0.02) 4.84E-01 20.01 (0.02) 4.58E-01
11q22.2 rs2124216 101644113 YAP1-BIRC3 A 4.50E-04 1.26 (1.11–1.43) 0.1963 0.12 (0.23) 6.00E-01 0.11 (0.23) 6.24E-01
12p13.31 rs728342 5577633 TMEM16B G 4.80E-02 1.14 (1.00–1.30) 0.1601 20.14 (0.22) 5.10E-01 20.18 (0.21) 4.08E-01
12q22 rs6538595 94030754 FGD6 A 1.70E-02 1.17 (1.03–1.34) 0.1136 20.37 (0.22) 9.15E-02 20.45 (0.21) 3.68E-02
19q13.12 rs1688005 40340205 FXYD5 G 3.80E-02 1.14 (1.01–1.29) 0.1244 0.17 (0.21) 4.27E-01 0.10 (0.20) 6.34E-01
20p12.1 rs1132274** 17544155 RRBP1 A 1.00E-02 1.23 (1.05–1.45) 0.1435 0.04 (0.02) 2.69E-02 0.03 (0.02) 1.37E-01
22q12.1 rs133885 24489289 MYO18B G 2.20E-01 1.08 (0.96–1.21) 0.1230 0.19 (0.19) 3.18E-01 0.30 (0.19) 1.16E-01
Association results with intracranial aneurysm (IA) by Yasuno and colleagues are followed by our meta-analysis association results with systolic blood pressure (SBP),
with the ROBUST and the ADVANCED models, respectively.
Table first shows association p-values with IA for the Finnish sub-group from the multinational GWAS (IA GWAS), followed by results from our meta-analysis of
association with systolic blood pressure (SBP) with the ROBUST and ADVANCED models. In the ROBUST model of association we corrected for gender and age and in
the ADVANCED model we further corrected for BMI, smoking habits and alcohol consumption.
Genomic positions are based on the human genome build 36. Alleles are reported on the forward strand of the reference genome. The effects are reported for the
alleles increasing risk for IA in the Yasuno et al. studies [12,13]. If SNP is intergenic, Gene represents the nearest gene. SNPs are directly genotyped unless otherwise
marked (* HM2 imputed SNP, ** 1000G+HM3 imputed SNP). Yasuno et al (2011) at 8q24.23 followed-up with rs1554349 instead of the lead SNP, rs6577930.
In bold: locus showing strongest association with SBP in meta-analysis.
#‘IA GWAS’ triplet column shows the Finnish sub-group (nFINN-IA-CASES=912, nFINN-CONTROLS=8180) association results on IA of the GWAS by Yasuno and colleagues,
except for the PPA results, which is not Finnish sub-group specific, but counted for the whole multinational cohort.
##PPA: posterior probability of association with IA as calculated by Yasuno and colleagues for the multinational IA GWAS.
$‘SBP meta-analysis with ROBUST model’ and ‘with ADVANCED model’ twin-columns show results of our candidate locus meta-analysis with SBP as the outcome
variable. SBP meta-analysis beta values are given for IA risk alleles.
OR: odds ratio, CI: confidence interval, SE: standard error.
doi:10.1371/journal.pgen.1002563.t002
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region markedly. The 4.7 kb region showing the strongest
association harbors a SREBP1 binding site. SREBP1 is a
transcription factor governing cellular lipid biosynthesis. High-
lighting its biological significance in vascular traits, non-synony-
mous mutations in SREBP1 cause spontaneous hypertension in
rats [27]. It is possible that common variants facilitate SREBP1
binding, and thus, as shown by Zhou and colleagues [28], cause
vascular SMC proliferation. We propose that this effect is
conveyed by PRDM6 activation.
Although both the location and the function of the gene
highlight PRDM6 as a likely candidate, it is not the only plausible
gene near the association signal. Centrosomal protein of 120 KD (short
form: Cep120) is just downstream from the region of association
(Figure 2). Cep120 is a centrosomal protein with preferentially high
expression in neuronal progenitors during development [29].
Cep120 could contribute to IA risk by causing perturbation in the
neurovascular niche.
This is the first study establishing a shared genetic background
at 5q23.2 for IA and its important risk factor, high blood pressure.
However, both IA [30,31] and hypertension [32] have shown
linkage to 5q23.2 in previous studies. Resequencing the genomic
region in families that previously showed linkage to 5q23.2 might
reveal penetrant variants causing familial IA or severe high blood
pressure, or possibly both. Notably, Vasan and colleagues [33]
found that rs17470137, less than 8 kb downstream from PRDM6,
is associated with aortic root size, a feasible proxy of blood
pressure [34].
GWAS are designed to identify associations, they do not prove
causality. Deep resequencing of the associated region may improve
the fine mapping and guide closer to the causative variant, or even
uncover it, although resequencing efforts of GWAS regions have
had limited success [35]. A further limitation of our study is that
we were unable to address whether the identified risk variant at
5q23.2 increases the risk of developing IA as a consequence of
elevated SBP (causality between high SBP and IA) or whether the
variant modifies vessel wall structure in a way that elevates SBP
and increases IA risk as a pleiotropic effect (Figure S3). A study
conducted in a cohort characterized both for IA and blood
pressure would likely be a more suitable way of addressing this
question. Unfortunately, to the best of our knowledge, such a
large-scale cohort does not currently exist. The identified risk
variant, however, is unlikely to confer its effect solely by increasing
blood pressure, as leading hypertension risk loci fail to show
association with IA (data not shown). Yet, the mechanical effect of
elevated BP on the vessel wall, likely exacerbates IA formation.
The significance of the association identified in our study awaits
confirmation in other ethnicities.
To further decipher the genetics of IA, it is important to test if
genetic links can be established between IA and other strong risk
factors, such as smoking and alcohol consumption. In conclusion,
our results highlight the link between IA and blood pressure.
Materials and Methods
Study Subjects
Four Finnish population-based cohorts were included in our
study (Table 4). These cohorts were not characterized for IA. We
utilized genome-wide genotyped participants with available blood
pressure data, excluding those on blood pressure medication and
those for whom blood pressure medication data was not available
(nexcluded=1373). In our two tier approach, the discovery cohort
(ndiscovery=1581) was a subsample of the H2000 [14]. The H2000
study was carried out in several regions of Finland from fall 2000
to spring 2001, and was designed to provide information on the
health of the Finnish population. A subset of this cohort, consisting
of metabolic syndrome cases and matched controls, was genotyped
and utilized in this analysis. The replication cohort (nreplication=
8312) consisted of the YFS (n=1874) [15,16], the NFBC1966
(n=5361) [17], and the HBCS (n=1077) [18]. YFS participants
were recruited from all around Finland for a large follow-up study
on cardiovascular risk factors in young individuals in 1980. Clinical
data are from the follow-up at age 27 performed in 2007. NFBC1966
comprises individuals born in 1966 in the two northernmost provinces
of Finland (Oulu and Lapland). Clinical examinations took place at the
follow-up at age 31 in 1997. The HBCS participants were recruited
from the Helsinki region. The study examines the impact of fetal
environmental factors on childhood and adult life. Clinical examina-
tions took place during 2001–2004. HBCS participants had the highest
average age (Figure S2).
The ICBP-GWAS represents a union of numerous prior blood
pressure GWAS consortia to create a discovery meta-analysis of
Figure 1. Cohort-wise effects of risk allele count on SBP. The higher median age in HBCS is reflected as higher systolic blood pressure (SBP)
and less consistent association. Error bars show standard error.
doi:10.1371/journal.pgen.1002563.g001
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of the ICBP-GWAS; however, this overlap does not represent a
significant risk for bias, due to the small relative contribution of
NFBC1966 to the ICBP-GWAS results.
Genotyping and Imputation
All Finnish cohorts were genotyped using Illumina arrays
(Illumina Inc. San Diego, CA, USA): Illumina Infinium HD
Human610-Quad BeadChip for H2000, Illumina Hu-
manCNV370-Duo BeadChip for NFBC1966, and Illumina
Human670K custom BeadChip for YFS and HBCS. For SNPs
to be successfully genotyped, a per individual and per marker
success rate minimum of 95% was defined as default. 36 out of 41
candidate SNPs were successfully genotyped in all cohorts. For
SNPs with no directly genotyped data available, we imputed
genotypes with MACH [36] using HapMap CEU from Phase II as
the reference panel (further referred to as HM2 imputed data). If a
SNP was not present in HM2 imputed data, we used genotypes
imputed with IMPUTEv2 using the 1000 Genomes pilot data
CEU panel (August 2009 haplotypes) combined with HapMap
Phase 3 (Public Release #2) haplotypes as the reference panel
[37], extended with Finnish specific HapMap Phase 3 haplotypes
[38] (further referred to as 1000G+HM3 imputed data). All
missing genotypes were imputed, so the number of individuals
included in the analyses for each SNP is the same and equals the
final number (Table 4).
IA Loci Association Analysis with Blood Pressure and
Meta-Analysis of Results
Candidate loci were selected based on IA GWAS results [13].
Loci associated with IA with PPA$0.1 were included (Table 2).
PPA was calculated as described by Yasuno et al [12]. Briefly, a
uniform prior probability of association of 1/10 000 was assumed
for all SNPs and used to provide a probabilistic measure of
evidence. We tested 41 SNPs from 19 independent loci. We
defined SBP, DBP, MAP, and PP as quantitative outcome
variables. MAP was counted as the average of SBP and DBP
Table 3. Meta-analysis results of 5q23.2 SNPs with systolic
blood pressure from all four Finnish cohorts and ICBP-GWAS
combined.
SNP Position Risk Allele beta (SE) p
rs570682 122477549 T 0.50 (0.11) 9.58E-06
rs2287696 122488231 A 0.57 (0.16) 8.13E-07
rs335206 122532465 C 0.41 (0.86) 2.00E-06
Genomic positions are based on the human genome build 36. Risk alleles are
aligned according to the forward strand of the reference genome. SE: standard
error.
doi:10.1371/journal.pgen.1002563.t003
Figure 2. Association with SBP around PRDM6: Meta-analysis results from the four Finnish cohorts. Square shapes represent genotyped
SNPs, circles imputed ones. Red arrow depicts the SREBP1 binding site. For each SNP, the symbol color indicates the SNP’s pairwise linkage
disequilibrium with the most significant SNP, rs163189, measured as r2. SNPs for which no recombination data is available from the 1000 Genomes
June 2010 CEU panel are in grey.
doi:10.1371/journal.pgen.1002563.g002
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We tested all 19 loci in the discovery cohort (H2000), and those
showing suggestive association (uncorrected p,0.1) with any
outcome variable were tested in the replication cohorts (YFS,
NFBC1966, and HBCS). Association analyses with an additive
genetic model were performed with ProbABEL [39] for HM2
imputed data, and with SNPTESTv2 [40,41] for 1000G+HM3
imputed data. The analyses were adjusted for age and gender
(ROBUST model), or for age, gender, smoking habits, alcohol
consumption, and BMI (ADVANCED model). Additionally, in
the metabolic syndrome case-control subset of the H2000 cohort
we corrected for case-control status in both models. Population
stratification was corrected for by calculating principal compo-
nents from genome-wide SNP data and including significant
principal components in the association models as covariates.
Association results were combined in a fixed effect meta-analysis
with MetABEL [39] for HM2 imputed data, and with
METAv1.2 [42] for 1000G+HM3 imputed data. The best result
at 5q23.2 in PRDM6 was tested for association in the ICBP-
GWAS [19] cohort of 200 000 individuals of European descent.
In the ICBP-GWAS association with SBP was tested by linear
regression assuming an additive model and correcting for age,
age-squared and BMI. To test the per-allele effect size of risk
alleles on blood pressure, we calculated the mean blood pressure
for the three genotypic states for the three 5q23.2 SNPs using
Plink v1.07 [43]. Results were plotted using the Microsoft Excel
charts function.
To further investigate the strongest associated locus, we
analyzed all 1000 Genomes variants, with minor allele frequency
greater than 1%, in and around PRDM6. We took uncertainty of
imputation into account by using the maximum likelihood
estimates of the reference allele counts as genotypes (these
estimates may be fractional and range from 0 to 2). Fine mapping
of the 5q23.2 region was performed with 1000G+HM3 imputed
data. Results were plotted with LocusZoom [44].
Supporting Information
Figure S1 Suggestive association with IA at 5q23.2 in GWAS
(Yasuno et al 2010) [12]. The association to IA is strongest in the
Finnish population, however, tendency is observable in other
populations as well. FI=Finnish, NL=Dutch, DE=German,
AN=mixed European cohort collected from Germany, Great
Britain, Hungary, The Netherlands, Switzerland and Spain.
JP2=Japanese cohort.
(PDF)
Figure S2 Age distributions in the Finnish cohorts. In the
NFBC1966 all were of the same age, since data utilized here were
collected when the participants of the birth cohort were 31 years
old. HBCS participants were older than the rest. (X-axis
density=number of cohort participants).
(PDF)
Figure S3 Comparing causality and pleiotropy as possible
explanations of the overlapping association between IA and SBP.
(PDF)
Table S1 Association results in the discovery cohort (H2000)
of representative SNPs from the 19 regions tested. Association
with systolic blood pressure (SBP), diastolic blood pressure
(DBP), mean arterial pressure (MAP) and pulse pressure (PP)
were tested with the ROBUST model (age and gender as
covariates).
(DOC)
Table S2 2q33.1 and 5q23.2 loci cohort-wise ADVANCED
model effect estimates and meta-analysis results with diastolic
blood pressure (DBP) and mean arterial pressure (MAP).
(DOC)
Text S1 Full list of The International Consortium for Blood
Pressure Genome-Wide Association Studies (ICBP-GWAS) co-
authors, with affiliations.
(DOC)
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Table 4. Summary of cohort characteristics.
Discovery Replication Meta
Characteristic H2000 YFS NFBC1966 HBCS TOTAL
WG genotyped, QC passed 2210 2019 5361 1676 11266
WG genotyped, QC passed NOT taking BP medications 1581 1874 5361 1077 9893
Included in ROBUST model analysis 1575 1855 5242 1043 9715
Included in ADVANCED model analysis 1575 1805 5031 1038 9449
SBP (Hgmm, mean (SD)) 132 (19) 120 (14) 125 (13) 142 (20) 127 (17)
DBP (Hgmm, mean (SD)) 83 (11) 75 (11) 77 (12) 88 (10) 79 (12)
MAP (Hgmm, mean (SD)) 107 (13) 98 (12) 101 (11) 115 (14) 103 (13)
PP (Hgmm, mean (SD)) 49 (14) 45 (9) 48 (11) 54 (15) 48 (12)
Age (years, mean (SD)) 49 (10) 38 (5) 31 (0) 61 (3) 38 (11)
Gender (male (%)) 809 (51) 840 (45) 2531 (48) 444 (41) 4624 (47)
BMI (mean (SD)) 27 (4) 25 (5) 25 (4) 27 (4) 25 (4)
WG: whole-genome, QC: quality control, BP: blood pressure, SBP: systolic blood pressure, DBP: diastolic blood pressure, MAP: mean arterial pressure, PP: pulse pressure,
BMI: body-mass index, SD: 1 standard deviation.
doi:10.1371/journal.pgen.1002563.t004
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